Investors must secure Concord Biotech shares ahead of the November 4 record date under the standard T+1 settlement framework to qualify for the corporate distribution. The board-approved initiative will issue 10.46 crore shares of Re 1 face value each, with official allotment set for November 5. The company holds a market capitalization of approximately Rs 12,172 crore, with RARE Enterprises and associates retaining roughly a 24% stake as of the FY27 September quarter. This capital adjustment takes place against a difficult trading backdrop, as the equity has dropped roughly 13% so far in 2026.
Key points
Market participants must acquire shares prior to the record date to ensure demat creditin…: Market participants must acquire shares prior to the record date to ensure demat crediting under SEBI's T+1 settlement cycle.
The company's recent share trajectory reflects weakness, declining over 11% in the past w…: The company's recent share trajectory reflects weakness, declining over 11% in the past week and 19% over the past year.
Despite recent monthly declines exceeding 15%, the pharmaceutical company retains a posit…: Despite recent monthly declines exceeding 15%, the pharmaceutical company retains a positive return of slightly over 3% across a three-year span.
Sources checked by our analysis pipeline: 1
Only those shareholders who hold Concord Biotech shares in their demat accounts as of Wednesday will be eligible to receive the bonus shares. As per Sebi's T+1 settlement cycle, investors must buy the company's shares at least one trading day before the record date for them to be credited to their demat accounts and qualify for the bonus issue. This makes today the last day to buy the stock to be eligible for the bonus shares.
Also read | Bonus issues, stock splits, dividends: Infosys, Asian Paints among over 40 stocks turning ex-date this week
All about Concord Biotech’s bonus issue
Concord Biotech announced in September that its board of directors considered and approved the issuance of bonus shares in the ratio of 1:1 by capitalising the company’s share premium account. The company would issue 10.46 crore bonus shares with a face value of Re 1 each as part of the corporate action.Later in October, Concord Biotech fixed November 4 as the record date for the purpose of determining the eligibility of shareholders set to receive the bonus shares, which…
Strong operational metrics fueled the logistics firm's market momentum following strategic freight rate increases and commercial volume growth. The results highlight effective cost rationalization and operational expansion across its domestic transport footprint. Concurrently, investor sentiment has been bolstered by a recently concluded equity repurchase program priced near peak valuation levels.
A sharp single-day rally of over 7% on November 2 pushed the energy conglomerate onto a technical momentum radar. The surge propelled the stock into a selective screen of eight Nifty 500 companies showing strengthening price action. Market participants track these technical indicators to gauge underlying trend strength and spot early signs of sustained buying pressure.
Regional market sentiment split as technology sector concerns collided with fresh monetary policy tightening across the Pacific. Investors faced headwinds stemming directly from guidance shared by the consumer electronics giant. Meanwhile, elevated borrowing costs introduced by central bankers signaled sustained pressure on broader economic growth.